Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease.

Journal: Journal of pediatric gastroenterology and nutrition
PMID: 38291692

Abstract

OBJECTIVES: Antibodies to infliximab (ATIs) are associated with loss of response in children with inflammatory bowel disease (IBD). We aimed to describe the effectiveness of strategies for treatment modification following ATI development in pediatric IBD: (1) treatment escalation; and (2) switching to another anti-TNF agent.

Authors

  • Jasmijn Z Jagt
    Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Koen W Holleman
    Faculty of Medicine, Amsterdam UMC, Academic Medical Centre, Amsterdam, The Netherlands.
  • Marc A Benninga
    Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Academic Medical Centre, Amsterdam, The Netherlands.
  • Johan E Van Limbergen
    Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Academic Medical Centre, Amsterdam, The Netherlands.
  • Nanne K H de Boer
    Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam University Medical Centre, VU University Amsterdam, Amsterdam, The Netherlands.
  • Tim G J de Meij
    Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Keywords

External Resources

Popular Topics
Recent Journals